Clinical Trial Update: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dapagliflozin for heart failure with preserved ejection fraction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2023-07-11